Literature DB >> 11928815

The molecular basis for anti-proteolytic and non-proteolytic functions of plasminogen activator inhibitor type-1: roles of the reactive centre loop, the shutter region, the flexible joint region and the small serpin fragment.

Troels Wind1, Martin Hansen, Jan K Jensen, Peter A Andreasen.   

Abstract

The serine proteinase inhibitor plasminogen activator inhibitor type-1 (PAI-1) is the primary physiological inhibitor of the tissue-type and the urokinase-type plasminogen activator (tPA and uPA, respectively) and as such an important regulator of proteolytic events taking place in the circulation and in the extracellular matrix. Moreover, a few non-proteolytic functions have been ascribed to PAI-1, mediated by its interaction with vitronectin or the interaction between the uPA-PAI-1 complex bound to the uPA receptor and members of the low density lipoprotein receptor family. PAI-1 belongs to the serpin family, characterised by an unusual conformational flexibility, which governs its molecular interactions. In this review we describe the anti-proteolytic and non-proteolytic functions of PAI-1 from both a biological and a biochemical point of view. We will relate the various biological roles of PAI-1 to its biochemistry in general and to the different conformations of PAI-1 in particular. We put emphasis on the intramolecular rearrangements of PAI-1 that are required for its antiproteolytic as well as its non-proteolytic functions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11928815     DOI: 10.1515/BC.2002.003

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  21 in total

1.  High-resolution structure of the stable plasminogen activator inhibitor type-1 variant 14-1B in its proteinase-cleaved form: a new tool for detailed interaction studies and modeling.

Authors:  Jan K Jensen; Peter G W Gettins
Journal:  Protein Sci       Date:  2008-08-25       Impact factor: 6.725

2.  A mechanism for assembly of complexes of vitronectin and plasminogen activator inhibitor-1 from sedimentation velocity analysis.

Authors:  Kenneth H Minor; Christine R Schar; Grant E Blouse; Joseph D Shore; Daniel A Lawrence; Peter Schuck; Cynthia B Peterson
Journal:  J Biol Chem       Date:  2005-05-19       Impact factor: 5.157

Review 3.  The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding.

Authors:  Marta Helena Kubala; Yves Albert DeClerck
Journal:  Cancer Metastasis Rev       Date:  2019-09       Impact factor: 9.264

Review 4.  Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders.

Authors:  Chi-Tso Chiu; De-Maw Chuang
Journal:  Pharmacol Ther       Date:  2010-08-10       Impact factor: 12.310

Review 5.  Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing.

Authors:  Veronica R Placencio; Yves A DeClerck
Journal:  Cancer Res       Date:  2015-07-15       Impact factor: 12.701

6.  Biochemical mechanism of action of a diketopiperazine inactivator of plasminogen activator inhibitor-1.

Authors:  Anja P Einholm; Katrine E Pedersen; Troels Wind; Paulina Kulig; Michael T Overgaard; Jan K Jensen; Julie S Bødker; Anni Christensen; Peter Charlton; Peter A Andreasen
Journal:  Biochem J       Date:  2003-08-01       Impact factor: 3.857

7.  Lithium inhibits Smad3/4 transactivation via increased CREB activity induced by enhanced PKA and AKT signaling.

Authors:  Min-Huei Liang; Jens R Wendland; De-Maw Chuang
Journal:  Mol Cell Neurosci       Date:  2007-11-09       Impact factor: 4.314

8.  The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas.

Authors:  Birgitte Vrou Offersen; Boye Schnack Nielsen; Gunilla Høyer-Hansen; Fritz Rank; Stephen Hamilton-Dutoit; Jens Overgaard; Peter A Andreasen
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

9.  Structural differences between active forms of plasminogen activator inhibitor type 1 revealed by conformationally sensitive ligands.

Authors:  Shih-Hon Li; Natalia V Gorlatova; Daniel A Lawrence; Bradford S Schwartz
Journal:  J Biol Chem       Date:  2008-04-24       Impact factor: 5.157

10.  Single fluorescence probes along the reactive center loop reveal site-specific changes during the latency transition of PAI-1.

Authors:  Tihami Qureshi; Cynthia B Peterson
Journal:  Protein Sci       Date:  2015-11-25       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.